This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
5 ETFs Riding High on the Biotech Comeback
by Sweta Killa
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Biotech ETFs That Outperformed Last Week
by Sweta Killa
Biotech ETFs was the biggest gainer last week.
Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs
by Sanghamitra Saha
Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.
The Zacks Analyst Blog Highlights: ITB, BBP, XSD, PRN, XRT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ITB, BBP, XSD, PRN, XRT
Beyond Clean Energy, 5 Sector ETFs Soaring to Record Highs
by Sweta Killa
As most corners of the market rallied on the slew of positive news, a few sectors scaled new highs. We have highlighted five ETFs from different sectors that hit all-time highs in the recent trading session.
4 ETFs to Play the Hot Events of Q4
by Sanghamitra Saha
The S&P 500 posted its best third-quarter gains since 2010 with an advancement of 8.5%. The gains could continue as the October-December period is normally gainful for the market.
Top-Performing ETFs of the Worst September Since 2011
by Sanghamitra Saha
After a superb August, September turned gloomy for Wall Street.
5 ETFs Shining Bright Amid September Selling
by Sweta Killa
The combination of lofty valuation, lack of additional fiscal stimulus package, election uncertainty and rising U.S.-China tensions weighed on investors' sentiment.
"Worst September in 18 Years"? 4 Sector ETFs Surviving Selloffs
by Sanghamitra Saha
After a superb August, September looks gloomy for Wall Street. Still,
A Guide to Biotech ETF Investing
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.